Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TIMOLIDE 10-25 vs ALDORIL 25
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Timolol is a non-selective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, reducing plasma volume and blood pressure.
Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.
Hypertension
Hypertension
One tablet (timolol 10 mg / hydrochlorothiazide 25 mg) orally once daily. May be increased to two tablets once daily if needed.
Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.
The terminal elimination half-life of timolol is approximately 4 hours in patients with normal renal function, but may be prolonged to 12-20 hours in patients with renal impairment or hepatic dysfunction. The half-life of hydrochlorothiazide is 6-15 hours.
7-16 hours (terminal). In renal impairment, half-life may exceed 24 hours, requiring dose adjustment.
Timolol is extensively metabolized in the liver primarily by CYP2D6; hydrochlorothiazide is not metabolized and is excreted unchanged in urine.
Methyldopa is metabolized primarily via hepatic conjugation and renal excretion; hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Timolol is primarily eliminated by renal excretion of unchanged drug and metabolites. Approximately 20% of a dose is excreted unchanged in urine, with the remainder as metabolites (mostly inactive). Fecal elimination accounts for less than 5%.
Renal: ~85% unchanged. Biliary/fecal: ~15% as metabolites.
Timolol is approximately 10-60% bound to plasma proteins (primarily albumin). Hydrochlorothiazide is about 40-70% bound to plasma proteins.
Methyldopa: less than 10% bound to plasma proteins. Hydrochlorothiazide: ~70% bound to plasma proteins (primarily albumin).
Timolol: Vd approximately 1.3-3.6 L/kg, indicating extensive tissue distribution. Hydrochlorothiazide: Vd approximately 0.8-1.2 L/kg.
Methyldopa: 0.3-0.6 L/kg (distributes widely, including CNS). Hydrochlorothiazide: 0.8-1.5 L/kg (distributes into extracellular fluid).
Oral bioavailability of timolol is approximately 50-75% due to first-pass metabolism. Hydrochlorothiazide bioavailability is about 65-70%. Ophthalmic timolol undergoes systemic absorption, with measurable plasma levels.
Methyldopa: oral bioavailability ~25% (first-pass metabolism). Hydrochlorothiazide: oral bioavailability ~60-80%.
GFR 30-50 m L/min: maximum dose of timolol 10 mg/hydrochlorothiazide 25 mg once daily. GFR <30 m L/min: contraindicated (hydrochlorothiazide ineffective, risk of thiazide accumulation).
GFR 30-50 m L/min: use with caution, reduce dose. GFR <30 m L/min: not recommended.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose; start with lowest dose (timolol 10 mg/hydrochlorothiazide 25 mg) and titrate cautiously. Child-Pugh C: contraindicated (risk of hepatic encephalopathy and beta-blocker toxicity).
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated due to methyldopa hepatotoxicity risk.
Not recommended; safety and efficacy not established in pediatric patients.
Not established; avoid use in children.
Start with lowest dose (timolol 10 mg/hydrochlorothiazide 25 mg once daily); monitor renal function, electrolytes, and heart rate. Avoid in patients with significant bradycardia or heart block.
Start at lowest dose (1 tablet daily); monitor for orthostatic hypotension, sedation, and electrolyte imbalance.
No FDA black box warning.
None
Exacerbation of angina or myocardial ischemia upon abrupt withdrawal,Bronchospasm in patients with asthma or COPD,Masking of hypoglycemia in diabetic patients,Electrolyte imbalances, hypokalemia, hypercalcemia, hyperuricemia due to hydrochlorothiazide,Fetal harm if used during pregnancy
May cause sedation, depression, positive direct Coombs test, hemolytic anemia, hepatotoxicity, fluid/electrolyte imbalance, and sensitivity reactions; monitor liver function, CBC, and electrolytes.
Bronchial asthma,Sinus bradycardia,Heart block greater than first degree,Cardiogenic shock,Overt cardiac failure,Anuria,Hypersensitivity to timolol or hydrochlorothiazide
Hypersensitivity to methyldopa, hydrochlorothiazide, or sulfonamides; active hepatic disease; anuria; history of methyldopa-induced liver disorders.
Avoid high-potassium foods (e.g., bananas, oranges, potatoes) as hydrochlorothiazide can cause potassium loss, but timolol may mask hyperkalemia. Limit salt intake to enhance blood pressure control. Consume alcohol moderately as it may potentiate hypotension. Take with food to reduce gastrointestinal upset.
Avoid high-sodium foods to optimize antihypertensive effect. Limit alcohol intake. Do not consume large amounts of potassium-rich foods (e.g., bananas, oranges, spinach) unless advised by a healthcare provider, as hydrochlorothiazide can alter potassium levels.
First trimester: Risk category D. Timolol (beta-blocker) and hydrochlorothiazide (diuretic) are associated with potential fetal bradycardia, hypoglycemia, and growth restriction. Thiazides may cause fetal electrolyte imbalances and jaundice. Second and third trimesters: Continued risk of fetal bradycardia, reduced placental perfusion, and neonatal complications (hypoglycemia, bradycardia, respiratory depression). Thiazides may cause oligohydramnios and neonatal thrombocytopenia.
First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios, and renal dysfunction due to methyldopa component. Hydrochlorothiazide may cause fetal electrolyte imbalances.
Timolol is excreted into breast milk (M/P ratio approximately 1.4). Hydrochlorothiazide is also present in low amounts. Due to potential for infant bradycardia, hypoglycemia, and electrolyte disturbances, use during breastfeeding is generally not recommended. If essential, monitor infant for signs of beta-blockade and thiazide effects.
Methyldopa is excreted in breast milk with M/P ratio of approximately 0.2-0.5; hydrochlorothiazide M/P ratio ~0.5-0.6. Considered compatible with breastfeeding by AAP, but monitor infant for hypotension and electrolyte disturbances.
Pregnancy may alter pharmacokinetics of timolol due to increased plasma volume and renal clearance. Hydrochlorothiazide efficacy may be reduced due to increased GFR. Dose adjustments should be guided by clinical response but no standard dose modification; use lowest effective dose.
No standard dose adjustment required, but increased plasma volume in pregnancy may necessitate higher doses of methyldopa. Monitor clinical response and adjust accordingly.
Timolide 10-25 contains timolol (a non-selective beta-blocker) and hydrochlorothiazide (a thiazide diuretic). Monitor heart rate and blood pressure closely due to risk of bradycardia and hypotension. Avoid abrupt discontinuation to prevent rebound hypertension. Use with caution in patients with asthma, COPD, or diabetes as beta-blockers can mask hypoglycemia. Check electrolytes and renal function periodically due to diuretic effects.
ALDORIL 25 is a fixed-dose combination of methyldopa (250 mg) and hydrochlorothiazide (25 mg). Monitor for hypotension, especially during initial therapy or with volume depletion. Methyldopa may cause a positive direct Coombs test and hemolytic anemia; discontinue if anemia develops. Hydrochlorothiazide can cause electrolyte imbalances, hyperglycemia, and hyperuricemia. Avoid use in patients with pheochromocytoma or active liver disease.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not stop taking this drug suddenly; consult your doctor before discontinuing to avoid a rapid rise in blood pressure.,Notify your doctor if you experience slow heartbeat, dizziness, fainting, or signs of electrolyte imbalance (e.g., muscle cramps, weakness, irregular heartbeat).,Avoid alcohol as it may increase dizziness or drowsiness.,Use caution when driving or operating machinery until you know how this medication affects you.,Keep all appointments for blood pressure and lab tests (e.g., potassium, sodium, kidney function).
Take this medication exactly as prescribed, usually once or twice daily.,Rise slowly from sitting or lying to prevent dizziness from low blood pressure.,Avoid alcohol, which can increase dizziness and drowsiness.,Report any signs of infection, unusual tiredness, or yellowing of skin/eyes.,Use sun protection as hydrochlorothiazide may increase sun sensitivity.,Do not use potassium supplements or salt substitutes without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TIMOLIDE 10-25 vs ALDORIL 25, answered by our medical review team.
TIMOLIDE 10-25 is a Antihypertensive Combination that works by Timolol is a non-selective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, reducing plasma volume and blood pressure.. ALDORIL 25 is a Antihypertensive Combination that works by Combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TIMOLIDE 10-25 and ALDORIL 25 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TIMOLIDE 10-25 is: One tablet (timolol 10 mg / hydrochlorothiazide 25 mg) orally once daily. May be increased to two tablets once daily if needed.. The standard adult dose of ALDORIL 25 is: Oral: 1 tablet (hydrochlorothiazide 25 mg/methyldopa 250 mg) twice daily; increase as needed to max 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TIMOLIDE 10-25 and ALDORIL 25 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TIMOLIDE 10-25 is classified as Category C. First trimester: Risk category D. Timolol (beta-blocker) and hydrochlorothiazide (diuretic) are associated with potential fetal bradycardia, hypoglycemia, and growth restriction. T. ALDORIL 25 is classified as Category C. First trimester: Limited human data, but animal studies show no teratogenicity at therapeutic doses. Second and third trimesters: Associated with fetal hypotension, oligohydramnios. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.